The tyrosine kinase receptor AXL of the TAM (TYRO3, AXL and MERTK) family is considered as a promising therapeutic target for different hematological cancers and solid tumors. AXL is involved in multiple pro-​tumorigenic processes including cell migration, invasion, epithelial-mesenchymal transition (EMT), and stemness, and recent studies demonstrated its impact on cancer metastasis and drug resistance. Extensive studies on AXL have highlighted its unique characteristics and physiological functions and suggest that targeting of AXL could be beneficial in combination with chemotherapy, radiotherapy, immunotherapy, and targeted therapy. In this mini review, we discuss possible outcomes of AXL targeting either alone or together with other therapeutic agents and emphasize its impact on triple negative breast cancer (TNBC).

TAM（TYRO3、AXL 和 MERTK）家族的酪氨酸激酶受体 AXL 被认为是不同血液癌症和实体瘤的有前景的治疗靶点。 AXL 参与多种促肿瘤过程，包括细胞迁移、侵袭、上皮间质转化 (EMT) 和干性，最近的研究证明了它对癌症转移和耐药性的影响。对AXL的广泛研究突显了其独特的特性和生理功能，并表明AXL的靶向与化疗、放疗、免疫治疗和靶向治疗相结合可能是有益的。在这篇小型综述中，我们讨论了 AXL 单独靶向或与其他治疗药物联合靶向的可能结果，并强调其对三阴性乳腺癌 (TNBC) 的影响。